![]() |
市场调查报告书
商品编码
1957250
自动化样品製备市场-全球产业规模、份额、趋势、机会、预测:按应用、产品类型、最终用户、地区和竞争格局划分,2021-2031年Automated Sample Preparation Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Application, By Product Type, By End-User, By Region & Competition, 2021-2031F |
||||||
全球自动化样品製备市场预计将从 2025 年的 24.2 亿美元成长到 2031 年的 43.1 亿美元,复合年增长率为 10.10%。
自动化样品製备是指在分析检体之前,利用机器人系统和软体协调生物或化学样本的萃取、纯化和处理过程。该市场的主要驱动因素包括迫切需要提高可重复性并减少可能威胁资料完整性的人为错误。此外,药物研发和临床诊断领域对快速处理能力的需求日益增长,也要求系统能够以符合现代实验室标准的速度和精度处理大量样本。
| 市场概览 | |
|---|---|
| 预测期 | 2027-2031 |
| 市场规模:2025年 | 24.2亿美元 |
| 市场规模:2031年 | 43.1亿美元 |
| 复合年增长率:2026-2031年 | 10.1% |
| 成长最快的细分市场 | 测量仪器 |
| 最大的市场 | 北美洲 |
随着实验室不断努力提高效率,采用先进技术已成为市场发展的关键要素。根据皮斯托亚联盟2024年的数据,68%的受访生命科学专业人士在其工作流程中积极使用人工智慧(AI)和机器学习,这表明智慧自动化系统能够简化复杂流程,并已形成良好的推广环境。然而,将这些平台与现有传统基础设施整合的复杂性是其广泛应用的主要障碍。此外,此类大型系统所需的大量前期投资也令小规模实验室望而却步,儘管其营运优势显而易见,但这可能会延缓其普及。
製药和生物技术公司研发投入的增加是全球自动化样品製备市场的主要驱动力。随着药物发现日益复杂,主要企业正投入创纪录的研发资金,以加速潜在候选药物的发现。资金的涌入推动了自动化解决方案的普及,因为这需要部署能够快速、准确地筛检庞大化合物库的高通量系统。例如,强生公司在其于2024年1月发布的2023年第四季及全年财报中披露,为推动产品线创新,公司在研发方面投入了创纪录的151亿美元。如此庞大的投资凸显了依赖自动化工作流程的紧迫性,透过加快研发进度和确保早期筛检阶段的资料可靠性,可以优化投资报酬率。
同时,人们对提高营运效率和降低人事费用的日益关注正在改变实验室的管理方式。各机构越来越多地采用自动化技术,以缓解熟练人员短缺的影响,并消除人工操作带来的不一致。西门子医疗于2024年7月对美国实验室专业人员进行的一项调查显示,89%的受访者认为自动化对于有效管理不断增长的检测量至关重要。透过将重复性任务委託给机器人系统,检查室可以显着提高处理能力,同时减少人为错误。根据Dispendix在2024年11月发布的报告显示,次世代定序(NGS)的自动化已被证实可将人工检体处理的需求减少高达80%,使科学家能够专注于高价值的分析和结果解读。
大规模自动化样品製备系统所需的大量前期投资是全球自动化样品製备市场的主要阻碍因素。儘管这些平台在可重复性和速度方面具有优势,但高昂的前期投资阻碍了大多数潜在用户,尤其是中小企业和学术研究机构,放弃手动方法。这项财务障碍不仅包括硬体购置成本,还包括软体整合、专业人员培训和持续维护等相关费用,造成复杂的预算障碍,延缓采购决策并限制市场渗透。
资金限制仍然是先进实验室技术广泛应用的一大障碍。根据皮斯托亚联盟2024年的报告,在接受调查的生命科学专业人士中,20%的人认为资金障碍是采用新技术的主要阻碍,这一比例比前一年增加了数十亿以金额为准。这种对价格承受能力日益增长的担忧凸显出,儘管智慧自动化系统具有许多操作优势,但预算限制仍然直接阻碍了其普及应用。因此,成本敏感型细分市场的成长率正在放缓,而资金雄厚的製药巨头对技术的采用有限,也导致整体潜在市场规模萎缩。
永续で环境に配虑したサンプル调製技术への移行は、研究所が环境负荷低减を目指す中で製品开発に影响を与えています。この动向は、厳格な企业治理要件への适合を図るため、消耗品由来のプラスチック废弃物の削减や自动化机器のエネルギー使用量低减を重视するものです。メーカー各社はこうした优先顺位の変化に対応すべく、环境に优しいシステムの设计を积极的に进めています。この业界の取り组みは、2024年11月にMy Green Labが発表した「2024年バイオテック・製薬业界のカーボンインパクト报告书」で数値化されており、分析対象企业の31%が1.5℃目标に沿った中期的なスコープ1および2の排放削减目标を设定していることが示されました。これに伴い、ベンダー各社は试薬消费量を削减するためのワークフロー再构筑や、永续な运営への需要増に対応する循环型経済の概念导入を进めています。
同时,对复杂微量样本进行高灵敏度处理的需求正推动基因组学和蛋白质组学工作流程自动化程度的提高。现代平台已超越简单的液体处理,以满足次世代定序(NGS) 的严格要求。精确的微量分装对于维持样本完整性至关重要,而这项技术进步使得以往只能手动操作的复杂通讯协定得以自动化。例如,贝克曼库尔特生命科学公司于 2024 年 4 月宣布,其与 Watchmaker Genomics 合作开发的自动化 RNA 文库製备方法能够处理低至 1 ng 的样本量,这便是灵敏度提升的一个具体例证。这凸显了市场正朝着先进自动化方向发展,以极少量的生物材料获得高度精确的结果。
The Global Automated Sample Preparation Market is projected to expand from USD 2.42 billion in 2025 to USD 4.31 billion by 2031, reflecting a compound annual growth rate of 10.10%. Automated sample preparation involves the use of robotic systems and software to orchestrate the extraction, purification, and management of biological or chemical specimens ahead of analytical testing. The primary forces propelling this market include the urgent need for enhanced reproducibility and the mitigation of manual errors that threaten data integrity. Furthermore, the escalating requirement for rapid throughput in drug discovery and clinical diagnostics demands systems that can manage substantial sample volumes with the speed and precision necessary to satisfy contemporary laboratory standards.
| Market Overview | |
|---|---|
| Forecast Period | 2027-2031 |
| Market Size 2025 | USD 2.42 Billion |
| Market Size 2031 | USD 4.31 Billion |
| CAGR 2026-2031 | 10.1% |
| Fastest Growing Segment | Instruments |
| Largest Market | North America |
The incorporation of sophisticated technologies is a crucial element in market development as laboratories aim for heightened efficiency. Data from the Pistoia Alliance in 2024 reveals that 68% of life science experts surveyed are actively utilizing Artificial Intelligence and Machine Learning in their workflows, indicating a favorable climate for adopting intelligent automated systems that simplify complex processes. Nevertheless, a major obstacle hindering widespread growth is the complexity of merging these platforms with established legacy infrastructures. Additionally, the substantial initial capital investment needed for such extensive systems creates a hurdle for smaller laboratories, potentially delaying universal adoption despite the evident operational advantages.
Market Driver
Increasing research and development investments by pharmaceutical and biotechnology companies serve as a major driver for the Global Automated Sample Preparation Market. As the complexity of drug discovery intensifies, leading industry participants are allocating record amounts of capital toward research to expedite the discovery of potential therapeutic candidates. This influx of funding requires the implementation of high-throughput systems capable of screening extensive compound libraries with both speed and accuracy, thereby fostering the adoption of automated solutions. For example, Johnson & Johnson reported in their 'Fourth-Quarter and Full Year 2023 Results' in January 2024 a historic R&D investment of $15.1 billion to fuel pipeline innovation. Such significant financial outlays highlight the essential reliance on automated workflows to optimize return on investment by accelerating development schedules and guaranteeing data reliability during early-stage screening.
Concurrently, the growing emphasis on operational efficiency and the reduction of labor costs is transforming laboratory management approaches. Facilities are frequently adopting automation to alleviate the effects of skilled staff shortages and to remove the inconsistencies linked to manual handling. A July 2024 survey of U.S. laboratory professionals by Siemens Healthineers found that 89% of respondents believe automation is necessary to effectively manage rising testing volumes. By assigning repetitive duties to robotic systems, laboratories can drastically increase throughput while reducing human error. According to Dispendix in November 2024, the incorporation of Next-Generation Sequencing (NGS) automation has demonstrated the ability to decrease manual sample processing requirements by up to 80%, enabling scientists to shift their attention to high-value analysis and the interpretation of results.
Market Challenge
The substantial initial capital required for extensive automated sample preparation systems serves as a major constraint on the Global Automated Sample Preparation Market. Although these platforms provide benefits in terms of reproducibility and speed, the significant upfront cost deters a large portion of prospective users, specifically small-to-medium-sized enterprises (SMEs) and academic research facilities, from moving away from manual methods. This financial barrier encompasses not only the hardware purchase but also costs related to software integration, specialized staff training, and continuous maintenance, resulting in a complicated budgetary obstacle that postpones procurement decisions and limits market reach.
Financial limitations persist as a quantifiable hindrance to the uptake of advanced laboratory technologies. In 2024, the Pistoia Alliance reported that 20% of surveyed life science professionals identified financial barriers as a principal challenge to adopting new technologies, representing an increase from the prior year. This growing apprehension regarding affordability underscores that, despite the operational benefits, budgetary constraints are directly impeding the universal deployment of intelligent automated systems. As a result, the market undergoes reduced growth rates in cost-sensitive segments, limiting the technology's reach to well-capitalized pharmaceutical leaders and decreasing the overall addressable market volume.
Market Trends
The transition toward sustainable and green sample preparation techniques is influencing product development as laboratories aim to reduce their environmental impact. This trend emphasizes cutting down on plastic waste from consumables and decreasing energy usage in automated instruments to comply with stringent corporate governance requirements. Manufacturers are actively designing eco-friendly systems to match these shifting priorities. This industry commitment is quantified by the '2024 Carbon Impact of Biotech & Pharma Report' from My Green Lab in November 2024, which noted that 31% of analyzed firms have established medium-term Scope 1 and 2 targets consistent with a 1.5°C pathway. Accordingly, vendors are restructuring workflows to lower reagent consumption and applying circular economy concepts to meet the growing demand for sustainable operations.
At the same time, the broadening of automation within genomic and proteomic workflows is being propelled by the need to handle complex, low-input samples with high sensitivity. Contemporary platforms are advancing past simple liquid handling to address the exacting requirements of Next-Generation Sequencing (NGS), where accurate low-volume dispensing is essential for maintaining sample integrity. This technological progression enables researchers to automate intricate protocols that were formerly restricted to manual performance. Illustrating this improvement in sensitivity, Beckman Coulter Life Sciences announced in April 2024, regarding their collaboration with Watchmaker Genomics, that their co-developed automated RNA library preparation method successfully accommodates input quantities as low as 1 ng. This highlights the market's shift toward advanced automation that facilitates high-fidelity outcomes from minimal biological material.
Report Scope
In this report, the Global Automated Sample Preparation Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:
Company Profiles: Detailed analysis of the major companies present in the Global Automated Sample Preparation Market.
Global Automated Sample Preparation Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report: